Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.
Statin therapy alone is often insufficient to achieve appropriate lowering of LDL cholesterol levels and additional therapies are needed to complement existing therapies.
Higher consumption of dietary cholesterol is significantly associated with a higher risk for incident CVD and all-cause mortality.
Long-term adherence to statins was associated in a linear fashion with decreased 5-year major adverse clinical events.
Researchers found high rates of dyslipidemia and abnormal HbA1c, including 2 cases of diabetes, after screening for cardiovascular risk factors in middle school students.
Researchers analyzed the genetic differences between homo- and heterozygous familial hypercholesterolemia in a pediatric population.
The risk for coronary artery disease in patients with asthma-COPD overlap syndrome who used statins was lower regardless of the duration of treatment.
There is a high prevalence of discordance in the reduction of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) in response to evolocumab treatment.
Statin adherence linked to significantly reduced risk for MACE.
Treatment with icosapent ethyl was associated with a substantial reduction in the risk of first, subsequent, and total ischemic events when compared with placebo in statin-treated patients with established cardiovascular (CV) disease or diabetes with other CV risk factors.
Canagliflozin reduced the risk for heart failure in the context of both reduced EF and preserved EF.
Want to read more?
Please login or register first to view this content.
Next post in Dyslipidemia